SUSMED,INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 534 JPY | -4.13% |
|
-5.65% | -60.00% |
| 2023 | SUSMED,Inc.(TSE:4263) added to S&P Global BMI Index | CI |
| 2022 | Walgreens Boots Alliance, Inc. Joins Sustainable Medicines Partnership | CI |
Valuation
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 14,707 | 29,547 | 8,933 | - | - |
| Enterprise Value (EV) 1 | 9,803 | 24,499 | 4,358 | 4,916 | 5,135 |
| P/E ratio | -57.1 x | -577 x | -19.5 x | -22.8 x | -105 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 46.5 x | 55.7 x | 25.8 x | 14.9 x | 6.87 x |
| EV / Revenue | 31 x | 46.2 x | 12.6 x | 8.19 x | 3.95 x |
| EV / EBITDA | -43 x | -573 x | -9.6 x | -12.8 x | -64.2 x |
| EV / FCF | -53.9 x | - | -9.19 x | -8.81 x | -23.3 x |
| FCF Yield | -1.86% | - | -10.9% | -11.4% | -4.28% |
| Price to Book | 3.03 x | 6.1 x | 2.02 x | 2.22 x | 2.27 x |
| Nbr of stocks (in thousands) | 16,198 | 16,562 | 16,728 | - | - |
| Reference price 2 | 908.0 | 1,784 | 534.0 | 534.0 | 534.0 |
| Announcement Date | 12/08/22 | 10/08/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | 316 | 530 | 346 | 600 | 1,300 |
| EBITDA 1 | -228 | -42.77 | -454 | -385 | -80 |
| EBIT 1 | -229 | -48 | -459 | -390 | -85 |
| Operating Margin | -72.47% | -9.06% | -132.66% | -65% | -6.54% |
| Earnings before Tax (EBT) 1 | -233 | -49 | -452 | -390 | -85 |
| Net income 1 | -233 | -50 | -457 | -390 | -85 |
| Net margin | -73.73% | -9.43% | -132.08% | -65% | -6.54% |
| EPS 2 | -15.90 | -3.090 | -27.40 | -23.40 | -5.100 |
| Free Cash Flow 1 | -182 | - | -474 | -558 | -220 |
| FCF margin | -57.59% | - | -136.99% | -93% | -16.92% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 12/08/22 | 10/08/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 251 | 37 | 28 | 31 | 32 | 63 | 434 | 33 | 32 | 233 | 265 | 42 | 46 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -45 | -96 | -88 | -91 | -98 | -189 | 278 | -137 | -150 | 53 | -97 | -130 | -169 |
| Operating Margin | -17.93% | -259.46% | -314.29% | -293.55% | -306.25% | -300% | 64.06% | -415.15% | -468.75% | 22.75% | -36.6% | -309.52% | -367.39% |
| Earnings before Tax (EBT) 1 | -88 | -58 | - | -92 | -97 | -189 | 279 | -139 | -145 | 55 | -90 | -127 | -162 |
| Net income 1 | -88 | -58 | -87 | -92 | -98 | -190 | 279 | -139 | -146 | 55 | -91 | -127 | -167 |
| Net margin | -35.06% | -156.76% | -310.71% | -296.77% | -306.25% | -301.59% | 64.29% | -421.21% | -456.25% | 23.61% | -34.34% | -302.38% | -363.04% |
| EPS | -6.590 | -3.700 | - | -5.720 | - | -11.68 | 17.13 | - | -8.790 | - | -5.490 | -7.610 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/02/22 | 13/05/22 | 12/08/22 | 11/11/22 | 10/02/23 | 10/02/23 | 12/05/23 | 10/08/23 | 10/11/23 | 14/02/24 | 14/02/24 | 10/05/24 | - |
1JPY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | 4,904 | 5,048 | 4,575 | 4,017 | 3,798 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | -182 | - | -474 | -558 | -220 |
| ROE (net income / shareholders' equity) | -7.3% | -1% | -9.9% | -9.3% | -2.1% |
| ROA (Net income/ Total Assets) | -4.34% | -0.88% | -9.4% | -8.8% | -2% |
| Assets 1 | 5,369 | 5,707 | 4,862 | 4,432 | 4,250 |
| Book Value Per Share 2 | 299.0 | 292.0 | 264.0 | 241.0 | 236.0 |
| Cash Flow per Share | -15.70 | -2.740 | - | - | - |
| Capex 1 | 17 | 18 | 10 | 10 | 10 |
| Capex / Sales | 5.38% | 3.4% | 2.89% | 1.67% | 0.77% |
| Announcement Date | 12/08/22 | 10/08/23 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -60.00% | 59.57M | |
| -12.61% | 193B | |
| +2.29% | 169B | |
| +2.60% | 154B | |
| +6.43% | 100B | |
| +11.32% | 80.96B | |
| +34.00% | 79.71B | |
| -7.97% | 70.64B | |
| -17.88% | 53.75B | |
| -9.09% | 42.84B |
- Stock Market
- Equities
- 4263 Stock
- Financials SUSMED,Inc.
